Abstract:Abstract Background Based on its low toxicity, arginine starvation therapy has the potential to cure malignant tumors that cannot be treated surgically. The Arginine deiminase (ADI) gene has been identified to be an ideal cancer-suppressor gene. ADI expressed in the cytosol displays higher oncolytic efficiency than ADI-PEG20 (Pegylated Arginine Deiminase by PEG 20,000). However, it is still unknown whether cytosolic ADI has the same mechanism of action as ADI-PEG20 or other underlying cellular mechanisms. Methods The interactions of ADI with other protein factors were screened by yeast hybrids, and verified by co-immunoprecipitation and immunofluorescent staining. The effect of ADI inhibiting the ferritin light-chain domain (FTL) in mitochondrial damage was evaluated by site-directed mutation and flow cytometry. Control of the mitochondrial apoptosis pathway was analyzed by Western Blotting and real-time PCR experiments. The effect of p53 expression on cancer cells death was assessed by siTP53 transfection. Chromatin autophagy was explored by immunofluorescent staining and Western Blotting. Results ADI expressed in the cytosol inhibited the activity of cytosolic ferritin by interacting with FTL. The inactive mutant of ADI still induced apoptosis in certain cell lines of ASS- through mitochondrial damage. Arginine starvation also generated an increase in the expression of p53 and p53AIP1, which aggravated the cellular mitochondrial damage. Chromatin autophagy appeared at a later stage of arginine starvation. DNA damage occurred along with the entire arginine starvation process. Histone 3 (H3) was found in autophagosomes, which implies that cancer cells attempted to utilize the arginine present in histones to survive during arginine starvation. Conclusions Mitochondrial damage is the major mechanism of cell death induced by cytosolic ADI. The process of chromatophagy does not only stimulate cancer cells to utilize histone arginine but also speeds up cancer cell death at a later stage of arginine starvation.

What problem does this paper attempt to address?

### What problems does this paper attempt to solve? This paper aims to explore the mechanism of action of arginine deiminase (ADI) expressed in the cytoplasm in cancer cells, especially whether it activates the mitochondrial apoptotic pathway and induces chromatin autophagy by interacting with ferritin light chain (FTL). Specifically, the paper addresses the following key issues: 1. **Mechanism of action of cytoplasmic ADI**: - To study whether ADI expressed in the cytoplasm has the same anti - tumor mechanism as PEG - modified ADI (ADI - PEG20). - To explore the specific mechanism of action of cytoplasmic ADI in cells and its impact on cancer cells. 2. **Interaction between ADI and FTL**: - To confirm the interaction between ADI and FTL and verify whether this interaction occurs in the cytoplasm. - To study how this interaction affects the function of ferritin and the impact on mitochondrial damage. 3. **Activation of the mitochondrial apoptotic pathway**: - To evaluate the changes in key molecules (such as p53, p53AIP1, Noxa, PUMA, CASP9 and CASP3) in the mitochondrial apoptotic pathway after ADI expression. - To verify the activation of the mitochondrial permeability transition pore (MPTP). 4. **Induction of chromatin autophagy**: - To study whether nutrient deprivation caused by ADI expression leads to the occurrence of chromatin autophagy. - To explore the impact of chromatin autophagy on cancer cell death, especially in the late stage of arginine deprivation. ### Background of the paper Arginine - deprivation therapy, as a low - toxicity tumor treatment method, shows the potential to cure inoperable malignant tumors. The ADI gene has been identified as an ideal cancer - suppressing gene, and ADI expressed in the cytoplasm has a higher oncolytic efficiency than ADI - PEG20. However, the specific mechanism of action of cytoplasmic ADI is still unclear, so further research is needed to determine its unique mechanism of action. ### Main findings 1. **Cytoplasmic ADI inhibits ferritin activity**: Cytoplasmic ADI inhibits the activity of ferritin in the cytoplasm by interacting with FTL. 2. **Mitochondrial damage and apoptosis**: Even in the presence of ADI - inactivated mutants, some ASS - negative cell lines still undergo apoptosis through mitochondrial damage. 3. **Up - regulation of p53 and p53AIP1**: Arginine deprivation increases the expression of p53 and p53AIP1, exacerbating mitochondrial damage. 4. **Chromatin autophagy**: Chromatin autophagy occurs in the late stage of arginine deprivation, and histone H3 appears in autophagosomes, indicating that cancer cells attempt to use arginine in histones to survive. ### Conclusion Cytoplasmic ADI mainly induces cell death through mitochondrial damage, while chromatin autophagy not only promotes cancer cells to use arginine in histones but also accelerates cancer cell death in the late stage of arginine deprivation. These findings provide important guidance for the optimization of the ADI gene in clinical applications.

Intracellular expression of arginine deiminase activates the mitochondrial apoptosis pathway by inhibiting cytosolic ferritin and inducing chromatin autophagy

Arginine Starvation Impairs Mitochondrial Respiratory Function in ASS1-Deficient Breast Cancer Cells

Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase

Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy

Arginine-Depleting Enzymes – An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies

Arginine Deiminase Inhibit Argininosuccinate Synthetase-Deficient PANC-1 Cell Invasion Via Suppression of Pi3K/Akt/Nf-κB Signal

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment

Arginine Signaling and Cancer Metabolism

Recombinant Arginine Deiminase from Levilactobacillus brevis Inhibits the Growth of Stomach Cancer Cells, Possibly by Activating the Intrinsic Apoptosis Pathway

Enhanced anti-cancer efficacy of arginine deaminase expressed by tumor-seeking Salmonella Gallinarum

Arginine Deiminase Augments the Chemosensitivity of Argininosuccinate Synthetase-Deficient Pancreatic Cancer Cells to Gemcitabine Via Inhibition of NF-κB Signaling

Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy

Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism

Investigation of fermentation process of arginine deiminase in Enterococcus faecalis

An Engineered Arginase FC Protein Inhibits Tumor Growth in Vitro and in Vivo.

Targeting arginine metabolism pathway to treat arginine-dependent cancers.

Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination

Arginine Deiminase Modulates Endothelial Tip Cells Via Excessive Synthesis of Reactive Oxygen Species.

Arginine starvation elicits chromatin leakage and cGAS-STING activation via epigenetic silencing of metabolic and DNA-repair genes

Study on the new target of the individual treatment of breast cancer by argininosuccinate synthetase 1